Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 8/20 | 0.85 |
| ▸ | ENPP2 | Q13822 | 8/20 | 0.85 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.85 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.75 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.74 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.74 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.74 |
| ▸ | CES2 | O00748 | 1/20 | 0.74 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.74 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.74 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.71 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.71 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.71 |
| ▸ | PRKCA | P17252 | 1/20 | 0.71 |
| ▸ | SELP | P16109 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30555867 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL3817083 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL235478 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL7700077 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL15328013 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL15328011 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL7698286 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL200646 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL17549876 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL30555910 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12226740-B2 | Stabilized filtration device | RETEIN AB (SE) | 2025-02-18 | — | — | US | claimed |
| US-11980688-B2 | Nanoliposome-microbubble conjugate including drug for hair loss treatment encapsulated in nanoliposome and composition for alleviating or treating hair loss containing same | MOOGENE MEDI CO., LTD. (KR) | 2024-05-14 | — | — | US | claimed |
| US-11944705-B2 | Nanoliposome-microbubble conjugate including drug for hair loss treatment encapsulated in nanoliposome and composition for alleviating or treating hair loss containing same | MOOGENE MEDI CO., LTD. (KR) | 2024-04-02 | — | — | US | claimed |
| US-11337923-B2 | Nanoliposome-microbubble conjugate including drug for hair loss treatment encapsulated in nanoliposome and composition for alleviating or treating hair loss containing same | MOOGENE MEDI CO., LTD. (KR) | 2022-05-24 | — | — | US | claimed |
| US-20220152559-A1 | STABILIZED FILTRATION DEVICE | RETEIN AB (SE) | 2022-05-19 | — | — | US | claimed |
| US-20220142922-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | THE GENERAL HOSPITAL CORPORATION | 2022-05-12 | — | — | US | claimed |
| US-20180177724-A1 | SITE-TARGETED NANO-LIPOSOMAL NITROGLYCERIN THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-06-28 | — | — | US | claimed |
| US-20180161272-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2018-06-14 | — | — | US | claimed |
| EP-3302436-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | The General Hospital Corporation (US) | 2018-04-11 | — | — | EP | claimed |
| WO-2016191556-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | THE GENERAL HOSPITAL CORPORATION (US) | 2016-12-01 | — | — | WO | claimed |
| WO-2014021678-A1 | MICROBUBBLE-NANOLIPOSOME COMPLEX FOR CANCER DIAGNOSIS AND TREATMENT | (주)아이엠지티 (KR) | 2014-02-06 | — | — | WO | claimed |
| US-20080160313-A1 | Lipid bilayers on nanotextured solid surfaces | ENERGY, U.S. DEPARTMENT OF | 2008-07-03 | — | — | US | claimed |
| US-5626867-A | LIPOSOME FOR CYTOTOXIC AGENTS | MAX-PLANCK GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1997-05-06 | — | — | US | claimed |
| EP-0630231-B1 | LIPOSOMES WITH EXCESS NEGATIVE CHARGE | MAX PLANCK GESELLSCHAFT (DE) | 1996-03-06 | — | — | EP | claimed |
| EP-0630231-A1 | LIPOSOMES WITH EXCESS NEGATIVE CHARGE. | MAX PLANCK GESELLSCHAFT (DE) | 1994-12-28 | — | — | EP | claimed |
| WO-1993018749-A1 | LIPOSOMES WITH EXCESS NEGATIVE CHARGE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1993-09-30 | — | — | WO | claimed |
| US-12605336-B2 | Fusogenic liposome-coated porous silicon nanoparticles | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260096988-A1 | DRUG DELIVERY METHODS AND COMPOSITIONS | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2026-04-09 | — | — | US | disclosed |
| US-5626867-A | LIPOSOME FOR CYTOTOXIC AGENTS | MAX-PLANCK GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1997-05-06 | — | — | US | disclosed |
| EP-0630231-B1 | LIPOSOMES WITH EXCESS NEGATIVE CHARGE | MAX PLANCK GESELLSCHAFT (DE) | 1996-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605336-B2 | Fusogenic liposome-coated porous silicon nanoparticles | NSF, FUS, STIM1 | LPAR1 618/4885ENPP2 2179/4885LPAR3 1091/4885 |
| US-20260096988-A1 | DRUG DELIVERY METHODS AND COMPOSITIONS | PCTP, LPXN, LITAF | LPAR1 327/4885ENPP2 1260/4885LPAR3 439/4885 |
| US-11337923-B2 | Nanoliposome-microbubble conjugate including drug for hair loss treatment encapsulated in nanoliposome and composition for alleviating or treating hair loss containing same | CYP11A1, SHH, AR | LPAR1 563/4885ENPP2 634/4885LPAR3 1260/4885 |
| US-11944705-B2 | Nanoliposome-microbubble conjugate including drug for hair loss treatment encapsulated in nanoliposome and composition for alleviating or treating hair loss containing same | CYP11A1, SHH, AR | LPAR1 563/4885ENPP2 634/4885LPAR3 1260/4885 |
| US-11980688-B2 | Nanoliposome-microbubble conjugate including drug for hair loss treatment encapsulated in nanoliposome and composition for alleviating or treating hair loss containing same | CYP11A1, SHH, AR | LPAR1 563/4885ENPP2 634/4885LPAR3 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.